Target- |
MechanismApoptosis stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
An open-label, dose-escalation, dose-expansion Phase 1 study to evaluate the tolerability, safety, pharmacokinetics/pharmacodynamics, and antitumor effect of ASCA101 in patients with advanced solid tumors
An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
100 Clinical Results associated with Metafines Co., Ltd.
0 Patents (Medical) associated with Metafines Co., Ltd.
100 Deals associated with Metafines Co., Ltd.
100 Translational Medicine associated with Metafines Co., Ltd.